Roclatan netarsudil/latanoprost: Completed Phase III enrollment

Aerie completed enrollment of about 690 patients in the double-blind, U.S. Phase III Mercury

Read the full 146 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE